Tag - SIOX

Developments

FDA grants Sio Gene fast track for gene therapy for GM2 gangliosidosis

Sio Gene Therapies (NASDAQ:SIOX) received fast track designation for AXO-AAV-GM2, an investigational gene therapy for the treatment of early infantile, late infantile, and juvenile-onset Tay-Sachs and Sandhoff disease...

November 1, 2021

Developments

Sio Gene presents positive interim Phase 1/2 data in GM1 gangliosidosis

Sio Gene Therapies (NASDAQ:SIOX) presented positive interim data from its ongoing Phase 1/2 study of AXO-AAV-GM1, its adeno-associated viral vector 9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

October 21, 2021

Feature

Sio Gene Therapies developing CNS-targeted gene therapies

Sio Gene Therapies (NASDAQ:SIOX) is pushing the boundaries of gene therapy to develop treatments for three debilitating neurodegenerative diseases, including clinical-stage product candidates in rare fatal pediatric...

July 6, 2021

Developments

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

Sio Gene Therapies (NASDAQ:SIOX) is presenting new biomarker data from the company’s study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

May 13, 2021

Markets

HCW starts Sio Gene Therapies at buy; PT $8

H.C. Wainwright initiated coverage of Sio Gene Therapies (NASDAQ:SIOX) with a “buy” rating and price target of $8. The stock closed at $2.70 on April 29. Sio is a gene therapy company with significant experience and...

April 30, 2021

Tag - SIOX

FDA grants Sio Gene fast track for gene therapy for GM2 gangliosidosis

Sio Gene presents positive interim Phase 1/2 data in GM1 gangliosidosis

Sio Gene Therapies developing CNS-targeted gene therapies

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

HCW starts Sio Gene Therapies at buy; PT $8

General

More